Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study on treatment modes for newly diagnosed overweight/obese type 2 diabetes after intensive intervention (EARLY follow-up)
ChiCTR2200062919Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin and empagliflozin in type 2 diabetes mellitus (T2DM), obesity and Overweight (3 arms), sponsored by Beijing Hospital. Primary endpoint: Diabetes remission rate at 12 months. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
metforminempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on ChiCTR2200062919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062919.